2018 MSGERC BIENNIAL MEETING

SEPTEMBER 25 - 28, 2018 Big Sky Resort Big Sky, Montana, USA

CLINICAL MYCOLOGY TODAY

2

USA

A warm welcome to all attendees, academic colleagues, fellows, scientists, faculty, government, and industry supporters. Thank you for participating in this 2nd Biennial Meeting of the Mycoses Study Group Education and Research Consortium. This meeting will provide state-of the-art lectures pertaining to many of the key clinical issues in mycology, and you will have ample time to discuss face to face the major challenges and priorities for clinical investigation in our field over the next 2 to 3 years. This is a working meeting, very interactive and collegial, and you will have the opportunity to spend meaningful time with other clinical and laboratory-based investigators, industry representatives, and investigators from the CDC and NIH. In addition, for the first time we are providing an opportunity for poster presentation by fellows in training and junior faculty. Our meeting venue at Big Sky Resort is majestic, peaceful, and relaxing, providing balance for our aggressive meeting schedule. Activities and sessions will take place in the following main areas: Missouri Ballroom Located in the Yellowstone Conference Center, all general sessions will take place here including Keynote, Plenary, and Q & A Discussions. Atrium Lounge Network with colleagues and hear what’s new with our sponsors. Huntley Dining Room Located near the Missouri Ballroom. We could not have our meeting without the support of our sponsors and educational grants. Please stop by each booth, hear what is new, and thank them for coming to Big Sky! I’m looking forward to a wonderful meeting together over the next few days. Sincerely,

Peter G. Pappas, MD President, MSGERC

3

USA

#1 CSF Lactate as a Marker of Disease Severity and Mortality in Cryptococcal Meningitis Mahsa Abassi, Ananta Bangdiwala, Darlisha Williams, Joshua Rhein, David Boulware, University of Minnesota, USA

#2 Coccidioidomycosis in Utah 2006-2015: Epidemiology, Clinical Characteristics and Outcomes Adrienne Carey, Brandon Webb, University of Utah School of Medicine, USA

#3 Attributable Mortality of Candidemia After Introduction of Echinocandins Florian Cornely, Oliver Cornely, Philipp Koehler, Felix Koehler, Sibylle Mellinghoff, University Hospital of Cologne, Germany

#4 FungiscopeTM - A Global Emerging Fungal Infection Registry Oliver Cornely, Danila Seidel, Philipp Kohler, Sibylle Mellinghoff, Jon Salmanton Garcia, Hilmar Wisplinghoff, Maria JGT Vehreschild, Janne Vehreschild, University Hospital of Cologne, Germany

#5 Using Genome Sequencing to Identify a Potential Rhizomucor Outbreak in Solid Organ Transplant Patients Tanis Dingle, Matthew Croxen, Amrita Bharat, Stephanie Smith, Michael Mulvey, University of Alberta, Canada

#6 Double Invasive Fungal Infection Due to Dematiaceous Moulds in a Renal Transplant Patient Guy El Helou, Elizabeth Palavecino, Marina Nunez, Mayo Clinic Rochester, USA

#7 Candida Pararugosa: First Reported Bloodstream Infection in an Adult Guy El Helou, Elizabeth Palavecino, Mayo Clinic Rochester, USA

#8 Impact of T2Candida Testing for Rapid Diagnosis of Candida Infections on Time to Therapy, Mortality, and Antifungal Stewardship at a Large Academic Center: A Retrospective, Single-Center Study Justin Hayes, Orlando Turner, Todd McCarty, Malia Manning, University of Alabama at Birmingham, USA

#9 Presentation and Outcome of Cryptococcal Infection Varies by Predisposing Illness Matthew Hevey, Krunal Raval, William Powderly, Andrej Spec, Washington University in St. Louis, USA

#10 Epidemiology and Outcome of Lomentospora Prolificans Infections in San Diego Martin Hoenigl, Jeffrey Jenks, Sharon Reed, Sanjay Mehta, University of California, San Diego, USA

#11 Epidemiology and Outcome of Fusarium Infections in San Diego Jeffrey Jenks, Martin Hoenigl, Sharon Reed, Sanjay Mehta, University of California, San Diego, USA

#12 Breakthrough Invasive Fungal Infections (IFI) in Acute Leukemia (AL) Patients Receiving Antifungal Prophylaxis Kathleen Linder, Anastasia Wasylyshyn, Caroline Castillo, Shiwei Zhou, Carol Kauffman, Marisa Miceli, University of Michigan, USA

#13 Clinical Application of Aspergillus Lateral Flow Device in Bronchoalveolar Lavage Fluid of Patients with Classic Risk Factors for Invasive Pulmonary Aspergillosis Kathleen Linder, Shiwei Zhou, Carol Kauffman, Marisa Miceli, University of Michigan, USA

#14 Clinical Application of AspID PCR Aline and in Combination with Aspergillus Lateral Flow Device in Bronchoalveolar Lavage Fluid of Patients with Classic Risk Factors for Invasive Pulmonary Aspergillosis Kathleen Linder, Melanie Flaherty, Shiwei Zhou, Jose Diaz, Carol Kauffman, Marisa Miceli, University of Michigan, USA

#15 The Ever Deepening Wound Poppy Markwell, John Dwyer, Yardley Brice, Alfred Luk, Tulane University, USA

#16 Impact of Antiretroviral Therapy Timing on Survival in Asymptomatic Cryptococcal Antigenemia Caleb Skipper, Radha Rajasingham, Elizabeth Nalintya, Joshua Rhein, David Meya, David Boulware, University of Minnesota, USA

Posters

4

USA

TRIPARTITE MISSION

In the new era of clinical research, the MSG Education & Research Consortium will continue to champion evidence-based diagnoses, prophylaxis, treatment, and management of invasive fungal infections through its tripartite mission:

Education Championing excellence and innovation in the development and delivery

of evidence-based medical knowledge in invasive fungal disease management for patients globally.

Research Translational thought leadership for the development

of diagnostics and medicinal antifungals for invasive fungal infections.

Scholarship Scholarly work to promote antifungal stewardship, investigational outbreak tracking,

implementation science, publications, and leadership.

Posters (continued)

#17 Comparison Between Endpoint and Real-Time Polymerase Chain Reaction for the Diagnosis of Pneumocystis Pneumonia Shiwei Zhou, Carol Kauffman, Michael Bachman, Marisa Miceli, University of Michigan, USA

#18 Rapid Urine Antigen Detection as a Diagnostic Test for Invasive Pulmonary Aspergillosis Kausik Datta, Seema Mehta, Darin Ostrander, Michelle Rock, Jesse Francis, Marta Feldmesser, Kieren Marr, Johns Hopkins University School of Medicine, USA

#19 SCY-078: A First-in-Class, Orally-Bioavailable, Glucan Synthase Inhibitor has Fungicidal Activity Against C. Auris, an Emerging, Multi-Drug Resistant Pathogen Stephen Barat, Katyna Borroto-Esoda, David Angulo, SCYNEXIS, Inc., USA

#20 Real World Evidence on the Burden of Illness Experienced by Patients with Systemic Mycoses Rhonda Schreiber, Gareth Lewis, Anna Forsythe, Jaclyn Hearnden, Mayne Pharma, Inc., USA

#21 In Vitro and in Vivo Evaluation of APZ001A/APX001 and Other GWT1 Inhibitors Against Cryptococcus Karen Shaw, Wiley Schell, Jonathan Covel, Gisele Duboc, Charles Giamberardino, Mili Kapoor, Molly Moloney, Amplyx Pharmaceuticals, USA

#22 Characterization of VL-2397 Antifungal Drug Mechanism of Action Sean Sullivan, Anna-Maria Dietl, Matthias Misslinger, Vasyl Ivashov, David Teis, Clemens Decristoforo, Larry Smith, Hubertus Haas, Vical Inc., USA

#23 Largest Study of Histoplasma Meningitis Debunks Assumptions of ID Physicians Joseph Wheat, Chade Hage, Thein Myint, Albert Anderson, James Riddell, MiraVista Diagnostics, USA

5

USA

Noon - 5:00 pm Registration and Welcome Refreshments

3:00 - 4:45 pm MSGERC Board of Directors Meeting

5:00 - 5:15 pm Welcome Remarks and Introductions ............................................................. Peter Pappas

5:15 - 8:00 pm Dinner and Sponsor Presentations

8:00 - 8:30 pm Q & A and Discussion

8:30 - 9:00 pm Overview of Wednesday

6:45 - 7:45 am Continental Breakfast

7:45 - 8:00 am Welcome ......................................................................................................... Peter Pappas

8:00 - 10:00 am Plenary Lectures: Candida Facilitators: Luis Ostrosky-Zeichner and Peter Pappas

▪ Updates on Candida Immunology ................................................................. Michail Lionakis ▪ Antifungal Resistance Among Candida spp .................................................. David Perlin ▪ What is New in Epidemiology and C. Auris ................................................... Tom Chiller ▪ Diagnostics .................................................................................................... Neil Clancy

10:00 - 10:30 am Refreshment Break and Visit Exhibits

10:30 - 12:30 pm Candida Facilitated Discussion with Q & A

12:30 - 1:30 pm Luncheon and Meet the Fellows

1:30 - 2:15 pm Biostatistics for Fungal Disease Trials: Special Considerations ....................... Gerald McGwin

2:15 - 4:15 pm Plenary Lectures: Cryptococcus Facilitators: John Perfect and David Boulware

▪ Host Response/Immunology ......................................................................... Liise-anne Pirofski ▪ The Fungus ................................................................................................... Andy Alspaugh ▪ Treatment Trials in Developing World .......................................................... David Boulware ▪ New Treatments for Cryptococcosis ............................................................. William Hope ▪ Cryptococcal Treatment Guidelines .............................................................. John Perfect

4:15 - 4:45 pm Refreshment Break and Visit Exhibits

4:45 - 6:00 pm Cryptococcus Facilitated Discussion with Q & A

6:00 - 7:00 pm Fellow Poster Sessions/Reception

7:00 - 8:15 pm Dinner/Business Meeting and MSGERC Update ............................................. Peter Pappas

8:15 - 9:00 pm Yellowstone Myths, Legends, and Lore ........................................................... Richard W. Jehle Presented by the South District Interpretive Ranger at Yellowstone National Park

Tuesday, September 25, 2018

Wednesday, September 26, 2018

6

USA

6:45 - 7:45 am Continental Breakfast

7:45 - 8:00 am Opening Welcome .......................................................................................... Peter Pappas

8:00 - 10:00 am Plenary Lectures: Aspergillus and Other Moulds Facilitators: Dimitrios Kontoyiannis and Marisa Miceli

▪ Aspergillus Diagnostics ................................................................................. P. Lewis White ▪ Prophylaxis and Treatment of IA in 2018 ..................................................... Dimitrios Kontoyiannis ▪ Insights into Antifungal Resistance, Newer Moulds ..................................... Nathan Wiederhold ▪ What is the Clinical Relevance of Antifungal Resistance? ........................... Tom Patterson (asp/moulds, New Trials)

10:00 - 10:30 am Refreshment Break and Visit Exhibits

10:30 - 12:30 pm Aspergillus and Other Moulds Facilitated Discussion with Q & A

12:30 - 1:30 pm Luncheon and Meet the Fellows

1:30 - 3:30 pm Plenary Lectures: Endemic and Other Mycoses Facilitators: Andrej Spec and GR Thompson

▪ Genetics, Evolutionary Biology, Environment .............................................. John Taylor ▪ Diagnostics .................................................................................................... GR Thompson ▪ Blastomyces, Emmonsia ............................................................................... Ilan Schwartz ▪ Histoplasmosis: Latin American Perspective ................................................ Ana Belen Arauz Rodriguez

3:30 - 4:00 pm Refreshment Break and Visit Exhibits

4:00 - 5:00 pm Endemic and other Mycoses Facilitated Discussion with Q & A

5:00 - 7:00 pm Break

7:00 - 9:30 pm Working Dinner Session: Facilitator Presentations Welcome: Peter Pappas

▪ Candida ......................................................................................................... Luis Ostrosky-Zeichner and Peter Pappas ▪ Cryptococcus ................................................................................................ John Perfect and David Boulware ▪ Aspergillus and Other Moulds ..................................................................... Dimitrios Kontoyiannis and Marisa Miceli ▪ Endemic and other Mycoses ........................................................................ Andrej Spec and GR Thompson ▪ Wrap-Up and Closing Remarks ..................................................................... Peter Pappas

6:30 - 8:30 am Scientific Committee and New Board Member Debrief Breakfast

Thursday, September 27, 2018

Friday, September 28, 2018

7

USA Presenters

Andrew Alspaugh, MD Professor Duke University School of Medicine Durham, North Carolina, USA Ana Belen Arauz Rodriguez, MD Attending Physician / Infectologist Hospital Santo Tomas Panama City, Panama David R. Boulware, MD, MPH Associate Professor University of Minnesota Minneapolis, Minnesota, USA Tom Chiller, MD, MPHTM Chief, Mycotic Diseases Branch Centers for Disease Control and Prevention Atlanta, Georgia, USA Cornelius (Neil) Clancy, MD Chief, Infectious Diseases VA Pittsburgh Healthcare System Pittsburgh, Pennsylvania, USA William Hope, PhD, FRACP, FRCPA Professor of Therapeutics and Infectious Diseases University of Liverpool Liverpool, United Kingdom Dimitrios Kontoyiannis, MD Professor for Cancer Research MD Anderson Cancer Center Houston, Texas, USA Michail Lionakis, MD, ScD Chief, Fungal Pathogenesis Section NIAID/National Institutes of Health Bethesda, Maryland, USA Gerald McGwin, Jr., MS, PhD Professor of Epidemiology and Director of Advanced Enterprise Analytics University of Alabama at Birmingham Birmingham, Alabama, USA

Tom Patterson, MD Professor and Chief, Infectious Diseases University of Texas Health San Antonio San Antonio, Texas, USA John R. Perfect, MD Chief, Division of Infectious Diseases Duke University Medical Center Durham, North Carolina, USA David S. Perlin, PhD Executive Director and Professor Rutgers New Jersey Medical School Newark, New Jersey, USA Liise-anne Pirofski, MD Chief, Division of Infectious Diseases Montefiore Medical Center and Albert Einstein College of Medicine Bronx, New York, USA Ilan Schwartz, MD, PhD, FRCPC Assistant Professor University of Alberta Edmonton, Alberta, Canada John Taylor, PhD Professor University of California Berkeley, The Taylor Lab Berkeley, California, USA George (GR) Thompson, MD Associate Professor of Clinical Medicine University of California, Davis Medical Center Sacramento, California, USA Nathan Wiederhold, PharmD Associate Professor University of Texas Health Science Center San Antonio, Texas, USA P. Lewis White, PhD Head of the Mycology Reference Laboratory Public Health Wales, Microbiology Cardiff Cardiff, United Kingdom

8

USA

President Peter Pappas, MD Professor University of Alabama at Birmingham Birmingham, Alabama, USA Treasurer Luis Ostrosky-Zeichner, MD, FACP Professor of Medicine McGovern Medical School Houston, Texas, USA Member at Large Oliver Cornely, MD Professor University Hospital of Cologne Cologne, Germany Member at Large Bart-Jan Kullberg, MD Professor of Medicine and Infectious Diseases Radboud University Nijmegen Nijmegen, The Netherlands Member at Large George (GR) Thompson, MD Associate Professor of Clinical Medicine University of California, Davis Medical Center Sacramento, California, USA

Non Voting Member Tom Chiller, MD, MPHTM Chief, Mycotic Diseases Branch Centers for Disease Control and Prevention Atlanta, Georgia, USA

President Elect John Perfect, MD Chief, Division of Infectious Diseases Duke University Medical Center Durham, North Carolina, USA Secretary Sharon Chen, PhD, MBBS, FRCPA, FRACP Director/Medical Microbiologist Centre for Infectious Diseases & Microbiology Associate Professor Sydney Medical School, University of Sydney

Sydney, NSW, Australia Member at Large Dimitrios Kontoyiannis, MD Professor for Cancer Research MD Anderson Cancer Center Houston, Texas, USA Member at Large Tom Patterson, MD Professor and Chief, Infectious Diseases University of Texas Health San Antonio San Antonio, Texas, USA Member at Large Theo Zaoutis, MD, MSCE Professor of Pediatrics Children’s Hospital of Philadelphia Philadelphia, Pennsylvania, USA Executive Director Carolynn Thomas Jones, DNP, MSPH, RN Associate Professor of Clinical Nursing The Ohio State University UAB School of Nursing Birmingham, Alabama, USA

2017 - 2018 MSCERC Board of Directors

MSGERC Staff Operations Manager Beth Kassalen, MBA MSGERC Headquarters Pittsburgh, Pennsylvania USA

Conference Manager Barbara Hamschin MSGERC Headquarters Pittsburgh, Pennsylvania USA

Staff Debbie Zaparoni MSGERC Headquarters Pittsburgh, Pennsylvania USA

9

USA

Dia

mon

d Le

vel

Plat

inum

Lev

el

Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at www.astellas.com.

Gilead Sciences, a research-based biopharmaceutical company, discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead has a rapidly expanding product portfolio, a growing pipeline of investigational drugs, and over 8,000 employees in offices across six continents. Millions of people around the world are living healthier lives because of therapies developed by Gilead. For more information, visit www.gilead.com.

Mayne Pharma is an Australian specialty pharmaceutical company focused on applying its drug delivery expertise to branded and generic pharmaceuticals. Mayne has a proud 30-year track record of innovation and success in developing and commercializing new oral drug delivery systems through our operations in Australia and North Carolina. Mayne is committed to bringing affordable quality medicines to patients with branded and generic products supporting dermatology, cardiology, women's health and oncology therapeutic areas. We are now expanding to infectious disease, with Mayne's reformulated itraconazole being studied by the MSGERC for the treatment of endemic mycoses. For more information, visit www.maynepharma.com.

10

USA

Gol

d Le

vel

Amplyx Pharmaceuticals is developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune compromised patients. Amplyx is advancing a novel small-molecule therapy, APX001, in clinical development. Intravenous and oral formulations of APX001 have been evaluated in a Phase 1 clinical program, with Phase 2 clinical trials in invasive fungal infections planned for initiation in 2018. For more information, visit www.amplyx.com.

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara intends to begin global Phase 3 trials in 2018 in the treatment and prophylaxis of invasive fungal infections to advance its novel echinocandin antifungal, rezafungin acetate (formerly CD101 IV). Cidara is also developing bispecific antibiotic immunotherapies through our Cloudbreak platform for the treatment of multi-drug resistant Gram-negative bacterial infections. For more information, visit www.cidara.com.

Matinas BioPharma is a biopharmaceutical company focused on enabling the delivery of life-changing medicines using its lipid nano-crystal ("LNC") drug delivery platform. Matinas' proprietary disruptive technology utilizes LNCs which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Matinas' product candidate, MAT2203, utilizes its LNC formulation technology for safe and effective delivery of broad-spectrum fungicidal agent, amphotericin B. Based on positive patient clinical data, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in acute lymphoblastic leukemia patients. For more information, visit www.matinasbiopharma.com.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

11

USA

Silv

er L

evel

F2G is a world-leading UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides, active against Aspergillus and other rare and resistant moulds, that act via a completely different mechanism than currently marketed agents. A Phase IIb Open Label study is currently ongoing focussing on azole resistant aspergilloses, scedosporiosis and other rare and resistant mould infections. Olorofim is being developed both as IV and oral formulations and promises to have a safe and well-tolerated profile. For more information, visit www.fgltd.com.

IMMY focuses primarily on manufacturing rapid, high-quality fungal diagnostics. With products for Cryptococcus (CrAg LFA), Histoplasma, Coccidioides (Coccidioides Ab LFA), Aspergillus (Aspergillus GM LFA), and Blastomyces, along with Mycobacteria specimen preparation reagents (MycoDDR), IMMY is setting the standard with accurate and affordable diagnostics for infectious diseases. Our goal is to create and distribute diagnostics that give health professionals and laboratorians a clear path of treatment for patients worldwide. IMMY is bridging the gap between fungal infections and proper treatment by Saving Lives One Diagnostic at a Time. For more information, visit www.immy.com.

Leadiant Biosciences, Inc. is a rare corporation dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Truly unique in its field, Leadiant Biosciences places its considerable scientific resources behind the discovery of compounds that benefit the few. Simply because it's the right thing to do. By maintaining an environment based on integrity, commitment, and placing the patient first, Leadiant Biosciences is able to consider what may be a small commercial success nothing less than a human triumph. For more information, visit www.leadiant.com.

MycoMed Technologies is a diagnostics firm developing urine-based tests for infectious diseases. We were spun out of Johns Hopkins based on the research of our CEO, Dr. Kieren Marr. Our first product is called MycoFlow-ASP, which is a urine-based, dipstick test for detecting pulmonary aspergillus infection. We are proceeding through clinical development and expect to have MycoFlow-ASP FDA-cleared early in 2019. We have additional development projects in place targeting a variety of fungal diseases as well as tuberculosis. Visit www.mycomedtechnologies.com for more information.

RealTime Laboratories, Inc., (RTL) is a Texas based clinical molecular biology and microbiology laboratory specializing in the detection of fungal elements and yeast as well as the metabolites of fungi founding human and environmental samples. At the forefront of the war on exposure to environmental toxins, RealTime Laboratories uses patented testing to help patients and their physicians determine the cause of illnesses related to environmental toxic mold exposure. In addition, we provide pre-clinical testing services for researchers, following the same high standards used in our clinical laboratory. Visit www.realtimelabs.com for more information.

We improve sepsis management by empowering clinicians to appropriately treat patients suspected of bloodstream infections faster than ever before. Early targeted therapy for pathogenic organisms may prevent bloodstream infections from progressing to sepsis. T2Direct Diagnostics™ suite of products are the first FDA-cleared tests that identify pathogenic organisms directly from whole blood in 3 to 5 hours without the wait of blood culture. Both the T2Bacteria® and T2Candida® Panels are run on the T2Dx® Instrument. Assay results provide data to clinicians helping to identify appropriate therapy faster, improve patient outcomes, advance stewardship, and reduce the cost of patient management. www.t2biosystems.com

12

USA

Silv

er L

evel

Viamet Pharmaceuticals discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs. For more information, visit www.viamet.com.

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on it vaccine technologies and other therapeutic approaches. Vical's antifungal product candidate, VL-2397, has a novel mechanism of action for the treatment of invasive fungal infections and low propensity for drug-drug interactions. A Phase 2 trial in invasive aspergillosis (IA) was initiated in February 2018. The US FDA has advised that VL-2397 is eligible for limited use indication approval in IA. In addition, FDA has granted Vical QIDP, Orphan Drug and Fast Track designations for VL-2397 in the treatment of IA. For more information, visit www.vical.com.

Oth

er C

ontr

ibut

ors

MiraVista Diagnostics is a CAP and CLIA accredited mycology reference laboratory with an exclusive focus on developing and processing diagnostic tests for serious fungal infections. We offer the highest standards in accuracy and sensitivity for detection and monitoring of Blastomyces dermatitidis, Histoplasma capsulatum, Cryptococcus, Coccidioides, Aspergillus and (1–3)-β-D glucan. MiraVista Diagnostics was founded in 2002 and serves the medical community in the U.S. and Canada. We offer same-day testing, superior sensitivity and specificity and direct access to the laboratory’s team of experienced infectious disease specialists. MiraVista serves reference laboratories, hospitals, healthcare systems and university medical centers. For more information, please visit www.miravistalabs.com or call 317-455-2153.

The MSGERC is a non-profit organization dedicated to providing continuing medical education and scientific/medical thought leadership for evidence-based medicine in the diagnoses, prevention, treatment and maintenance of patients at risk for or afflicted with invasive fungal infections. For more information, visit www.msgerc.org as well as www.drfungus.org, the educational website of MSGERC.

Educ

atio

nal G

rant

s

Leadiant Biosciences, Inc. is a rare corporation dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Truly unique in its field, Leadiant Biosciences places its considerable scientific resources behind the discovery of compounds that benefit the few, simply because it's the right thing to do. By maintaining an environment based on integrity, commitment, and placing the patient first, Leadiant Biosciences is able to consider what may be a small commercial success nothing less than a human triumph. Www.leadiant.com.

For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.

13

USA

DoctorFungus is your go-to resource for the most up-to-date information, education, and news in the world of medical mycology, as well as a valuable resource for patients and

caregivers who are dealing with these serious and rare diseases. Provided by the MSGERC as a primary educational resource, visit www.drfungus.org to contribute to the website, read

about the Case of the Month, or sign up to receive emails.

www.drfungus.org

Become a Member of MSGERC Today Membership of the Mycoses Study Group Education and Research Consortium includes many benefits: Website presence Eligibility to serve as a leader on a MSGERC standing committee Reduced registration rates for MSGERC Meetings Unparalleled access to a global community network of experts and renowned leaders in the Mycoses field Opportunities to serve as a subcontractor on MSGERC CME or research consultations Have a voice in the future and direction of diagnoses, prevention, treatment and cure of invasive fungal infections around the world Join MSGERC today for only $100/year. Stop by the MSGERC registration desk during the meeting or join online www.msgerc.org.

Thank You to the MSGERC 2018 Biennial Meeting Committee

Peter Pappas (Chair), University of Alabama Birmingham, Alabama, USA Oliver Cornely, University Hospital of Cologne Cologne, Germany Marisa Miceli, University of Michigan Ann Arbor, Michigan, USA Luis Ostrosky-Zeichner, McGovern Medical School Houston, Texas, USA John Perfect, Duke University Medical Center Durham, North Carolina, USA Tom Patterson, University of Texas Health San Antonio San Antonio, Texas, USA Adrej Spec, Washington University in St. Louis St. Louis, Missouri, USA

For more information, visit amplyx.com

ADVANCING NOVEL THERAPEUTIC SOLUTIONS for life-threatening infections

APX001

• First-in-class, highly differentiated IV and oral drug candidate for life threatening invasive fungal infections

• Novel target and MOA with broad-spectrum preclinical efficacy in multi-drug resistant strains including Candida, Aspergillus and rare molds

Focused on developing new anti-infectives that have the potential to transform the standard of

care and save or improve patients’ lives.

For more information, visit cidara.com.

A New Hope for Serious Infections

PROUD SUPPORTERS OF MSGERC

CidaraTherapeutics.indd 1 8/31/18 4:45 PM

Enabling the Delivery of Life-Changing Medicines

Matinas BioPharma is proud to be a supporter of the

Mycoses Study Group Education and Research Consortium

Utilizing our lipid nano-crystal (LNC) platform, a natural, nontoxic, and highly efficient drug formulation technology for the targeted intracellular delivery of a broad range of molecules.

Matinas BioPharma, Inc.

info@matinasbiopharma.comwww.matinasbiopharma.com

Lead platform-validating asset, MAT2203, with an initial indication for the prevention of invasive fungal infections in acute lymphoblastic leukemia patients, has the potential to address unmet medical need. scynexis.com

Jersey City, NJ USA

Mission: We are committed to positively impactingthe lives of patients suffering fromdifficult-to-treat and often life-threateninginfections by delivering innovative therapies.

SCY-078Novel, first-in-class IV/oral Triterpenoidwith broad-spectrum activity against: • Candida • Aspergillus • Pneumocystisincluding resistant strains

AdvancingTherapeutics,Improving Lives.

For more information, please visit www.gilead.com.© 2015 Gilead Sciences, Inc.

For more than 25 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.

GILEAD IS A PROUD SUPPORTER OF THE NATIONAL CONFERENCE ON SOCIAL WORK AND HIV/AIDS.

All trademarks and registered trademarks are owned or licensed by Mayne Pharma

Introducing Mayne Pharma

Mayne Pharma is an Australian specialty pharmaceutical company

focused on applying its drug delivery expertise to commercialize branded

and generic pharmaceuticals.

Our key marketed branded products include:

Infectious Disease• Lozanoc™ (SUBA™-itraconazole) capsules* used to treat

fungal infections using SUBA technology• Doryx® & Doryx®MPC (delayed-release doxycycline) tablets

used to treat acne, certain bacterial infections or as an anti-malarial

*SUBA-itraconazole 65mg capsules pending FDA approval

Astellas is a proud sponsor of the MSGERC 2018 Biennial MeetingNavigate to the Astellas booth and learn about our portfolio of products

CRESEMBA®, Astellas®, and the flying star logo are registered trademarks of Astellas Pharma Inc. ©2018 Astellas Pharma US, Inc. All rights reserved. Printed in USA. 026-0822-PM-6/18

KJob Number: 22426Revision Nm: 0Date: 06/15/18

YMC075-55156